(EP2911510) Medicinal treatment of dermal diseases in companion animals with norketotifen 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
(EP2911510) Medicinal treatment of dermal diseases in companion animals with norketotifen
公开号/公开日
EP2911510EP2911510EP2911510 / 2019-07-312016-06-012015-09-02
申请号/申请日
EP13848247 / 2013-10-21
发明人
ABERG A K GUNNARCIOFALO VINCENT B;
申请人
BRIDGE PHARMA;
主分类号
IPC分类号
A01N-043/40 A61K-031/445 A61K-038/13 A61P-017/00 A61P-017/04 A61P-031/00
摘要
(EP2911510) The methods disclosed herein relate to the treatment of dermal disorders, such as for example atopic dermatitis, in dogs, by administering a therapeutically effective amount of norketotifen. Therapeutic antimicrobial activity of norketotifen against Malassezia sp. is also described.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
(EP2911510) Harris, Oliver John Richard ; Novagraaf UK ([GB]) Reg. Nb: 101464856
代理机构
;
优先权号
2012US-61717240 2013US-13739090 2013US-14025302 2013WO-US65847
主权利要求
(EP2911510) 1. RS-norketotifen or a pharmaceutically acceptable salt thereof for use in a method for treating a pruritic and/or inflammatory dermal disorder in a dog in need of such treatment, said method comprising orally administering to the dog in need a therapeutically effective amount of said RS-norketotifen or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount of RS-norketotifen does not produce sedative side effects upon administration to the dog. 2. RS-norketotifen or a pharmaceutically acceptable salt thereof for use according to claim 1, wherein said dermal disorder is canine atopic dermatitis. 3. RS-norketotifen or a pharmaceutically acceptable salt thereof for use according to claim 1, wherein the amount of said RS-norketotifen or pharmaceutically acceptable salt thereof is 0.5 mg/kg bodyweight to 20 mg/kg bodyweight, expressed as free base and dosed once or twice daily in said method. 4. RS-norketotifen or a pharmaceutically acceptable salt thereof for use according to claim 1, where in said method said amount of RS-norketotifen is initially co-administered for one to four weeks of therapy with a corticosteroid in a therapeutically active dose, thereafter followed by monotherapy with RS-norketotifen. 5. RS-norketotifen or a pharmaceutically acceptable salt thereof for use according to claim 1, where in said method said RS-norketotifen is co-administered with a therapeutically effective dose of a corticosteroid. 6. RS-norketotifen or a pharmaceutically acceptable salt thereof for use according to claim 1, where in said method said amount of RS-norketotifen is co-administered with an immunosuppressant drug. 7. Norketotifen or a salt or isomer thereof and a pharmaceutically acceptable excipient for use in a method of treating a skin infection in a dog or cat, said method comprising administering to the dog or cat with a skin infection a topical formulation comprising a therapeutically effective amount of said norketotifen or a salt or isomer thereof and a pharmaceutically acceptable excipient, wherein the infection is a fungal infection or a bacterial infection. 8. Norketotifen or a salt or isomer thereof and a pharmaceutically acceptable excipient for use according to claim 7, where in said method the topical formulation is administered to an infected skin lesion and/or infected areas adjacent to the skin lesion on the dog or cat. 9. Norketotifen or a salt or isomer thereof and a pharmaceutically acceptable excipient for use according to claim 7, wherein the infection is a fungal infection and the fungus is Malassezia sp. or Candida albicans. 10. Norketotifen or a salt or isomer thereof and a pharmaceutically acceptable excipient for use according to claim 7, wherein the infection is a bacterial infection and the bacteria is Staphylococcus aureus. 11. Norketotifen or a salt or isomer thereof and a pharmaceutically acceptable excipient for use according to claim 7, wherein said method further comprises orally administering a composition comprising RS-norketotifen and a pharmaceutically acceptable excipient. 12. Norketotifen or a salt or isomer thereof and a pharmaceutically acceptable excipient for use according to claim 7, wherein the skin infection is a hot spot. 13. Norketotifen or a salt or isomer thereof and a pharmaceutically acceptable excipient for use according to claim 7, wherein the topical formulation contains the norketotifen or salt or isomer thereof at a concentration of 0.01 percent to 20.0 percent by weight.
法律状态
GRANTED
专利类型码
B1A4A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部